We are immensely thankful to the trial participants and their families for their time and commitment to this critical research effort." In June 2020, Amylyx announced the PEGASUS trial completed enrollment and dosed 96 participants. Following brief disruptions due to the coronavirus pandemic, including trial site closures, the trial team worked to prioritize patient safety and mitigate delays by capping trial enrollment four patients shy of the planned 100. Amylyx worked with site investigators and clinic teams to facilitate remote visits and expand visit windows when possible. Topline results are targeted for the first half of 2021. The PEGASUS trial will provide data on the safety and tolerability profile of AMX0035 in people with Alzheimer's disease, its biological activity on biomarkers related to disease processes and preliminary information on cognitive and functional effects of AMX0035. Alzheimer's disease affects memory, thinking and behavior.